The guy can only see our drug through the lens of a preconceived notion about oxidative stress. No doubt that could be a fringe cause of AD but it certainly isn't the only or the main cause. Luckily for us bryostatin does benefit oxidative stress. It's been proven in multiple research studies as well as the MS study.
You never read him talk about our actual MOA of synaptogenesis. That is a real MOA and bryostatin does increase the factors that lead to better synaptic health. That is NOT in question. Nor is the ability to regrow synapses. That's a biological fact.
Alzheimer's drugs have failed in part because mice don't get alzheimer's so the plaque models are manufactured. It's not real world studies. What mice do have are synaptic networks that do impact their cognition same as humans do. There is no reason to believe that drugs that can benefit mice synapses and thus their memory, can not be replicated in humans. That's the simple fallacy the market promotes. JMHO
News 
Market Data 
Discover 
AI
